It expands the spectrum of pathogenic APTX mutations associated with AOA1 and emphasizes the need of for genetic testing in patients with inherited movement disorders in patients from the Middle East, to assess the spread of founder mutations among consanguineous families. This evidence concerns the gene APTX and movement disorder.